Prostate cancer is an inflammatory disease; however, we found that 4/11 (36.4%) inflammatory markers (IL-8, IL-1β, NSE, and IL-6 levels) were significantly lower in the PCa patients. This evidence concerns the gene ENO2 and prostate carcinoma.